Oral Administration Sericin-Curcumin Nanoconjugates Inhibits Inflammation and Epithelial-Mesenchymal Transition to Treat Renal Interstitial Fibrosis Article Swipe
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-2360595/v1
· OA: W4311468645
Background: Chronic kidney disease (CKD) is the most common renal disease. Renal interstitial fibrosis (RIF) is an important marker of the progression of chronic kidney disease. Epithelial-interstitial transformation (EMT) and the release of inflammatory factors are the core mechanisms underlying RIF. Results: A type of orally administered nanoconjugate composed of curcumin and sericin was successfully synthesized. Following unilateral ureteral obstruction (UUO) in mice, oral gavage of nanoconjugates could significantly downregulate cytokines and proteins that participate in fibrosis in vivo. Conclusion: In general, sericin-curcumin nanoconjugate dosing via oral administration is an easy and effective therapeutic strategy for suppressing or even reversing the progression of renal interstitial fibrosis.
